NCT01822678View on ClinicalTrials.gov

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

161

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

November 30, 2006

Study Completion Date

November 30, 2006

Conditions
Bipolar I Disorder
Interventions
DRUG

Eslicarbazepine Acetate

Eslicarbazepine Acetate, starting with 800 mg per day and up-titrated in 800 mg steps until 2400 mg (maximum dose) according to clinical response.

DRUG

Eslicarbazepine Acetate

Eslicarbazepine Acetate, starting with 600 mg per day and up-titrated in 600 mg steps until 1800 mg (maximum dose) according to clinical response.

DRUG

Placebo

Placebo

All Listed Sponsors
lead

Bial - Portela C S.A.

INDUSTRY

NCT01822678 - Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder | Biotech Hunter | Biotech Hunter